Cumberland Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUMBERLAND, and when can generic versions of CUMBERLAND drugs launch?
CUMBERLAND has eight approved drugs.
There are seventeen US patents protecting CUMBERLAND drugs.
There are one hundred and thirty-one patent family members on CUMBERLAND drugs in thirty-eight countries and fourteen supplementary protection certificates in twelve countries.
Drugs and US Patents for Cumberland
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cumberland Pharms | ACETADOTE | acetylcysteine | INJECTABLE;INTRAVENOUS | 021539-001 | Jan 23, 2004 | AP | RX | Yes | Yes | 8,399,445 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | DISCN | Yes | No | 7,531,623 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cumberland Pharms | ACETADOTE | acetylcysteine | INJECTABLE;INTRAVENOUS | 021539-001 | Jan 23, 2004 | AP | RX | Yes | Yes | 8,653,061 | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cumberland
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | 6,727,286 | ⤷ Try a Trial |
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 7,208,471 | ⤷ Try a Trial |
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 6,635,618 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUMBERLAND drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 200 mg/mL, 30 mL vials | ➤ Subscribe | 2012-04-04 |
➤ Subscribe | Transdermal System | 3.1 mg/24 hrs | ➤ Subscribe | 2015-10-09 |
International Patents for Cumberland Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Denmark | 1589956 | ⤷ Try a Trial |
European Patent Office | 1678201 | ⤷ Try a Trial |
Canada | 2867477 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cumberland Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1292612 | 36/2011 | Austria | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
1292612 | 11C0051 | France | ⤷ Try a Trial | PRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
1292612 | 2011C/045 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VIBATIV - TELAVANCINE; AUTHORISATION NUMBER AND DATE: EU/1/11/705-001 20110902 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.